A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics. REPOSIT.
Vemurafenib (960mg BID) and Cobimetinib (60mg QD)
In: Patient with unresectable stage IIIc or stage IV confirmed BRAF mutation-positive metastatic melanoma, no prior RAF or MEK pathway inhibitor treatment, evaluable disease by CT and PET, ECOG performance status of 0-1. Ex: symptomatic brain metastases, impaired cardiac function, retinal disease.
Prof. J.B.A.G. Haanen / Dr. A.J.M. van den Eertwegh